0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Shanrong Biotechnology
Its shares trade under the ticker SRBT. It has been listed since 1 December 2008.
Shanrong Biotechnology Corp. operates as a shell company. The company is headquartered in Exton, Pennsylvania. The company went IPO on 2008-12-01. The firm is engaged in the fields of Defense, security and energy. The company provides refurbishment and upgrade of armored vehicles and the provisioning of spare parts and equipment for military and police forces around the world.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Industrials
- Industry
- Aerospace & Defense
- Listed since
- 1 Dec 2008
- Employees
- 3
Leadership
Pay as last reported
- Col. Timothy RinggoldChief Executive Officer, Director$1.1m
- Gina RinggoldChief Financial Officer, Secretary, Director, since 2008
- Avraham GilatDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Shanrong Biotechnology Corp has a strong research and development team that constantly innovates and develops new products to meet market demands.
- The company has a well-established brand reputation and a large customer base, providing a competitive advantage in the biotechnology industry.
- Shanrong Biotechnology Corp has advanced manufacturing facilities and technologies, enabling efficient production processes and high-quality products.
- The company has established strategic partnerships with key suppliers and distributors, ensuring a steady supply chain and wide market reach.
Weaknesses
- Shanrong Biotechnology Corp may face challenges in terms of regulatory compliance due to the highly regulated nature of the biotechnology sector.
- The company's heavy reliance on a single product line for revenue generation exposes it to the risk of market fluctuations and potential disruptions.
- Limited geographic diversification of the company's operations makes it vulnerable to regional economic and political uncertainties.
Opportunities
- The growing demand for biotech products and therapies worldwide presents a significant opportunity for Shanrong Biotechnology Corp to expand its market presence.
- Exploring partnerships and collaborations with research institutions and pharmaceutical companies can help the company leverage synergies and access new technologies.
- Expanding into new geographical markets can increase the company's revenue potential and reduce dependence on a single region.
Threats
- Intense competition from established biotech firms and new market entrants poses a threat to Shanrong Biotechnology Corp's market share and profitability.
- Evolving regulatory frameworks and potential changes in government policies can affect the company's operations and require costly compliance measures.
- Technological advancements and the emergence of alternative therapies may diminish the demand for the company's existing products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.